Nemocnice Jihlava prispevkova organizace
- Address
- lock Available on a paid plan
Nemocnice Jihlava - Neurology and Cardiovascular Research Center
Nemocnice Jihlava prispevkova organizace is a distinguished research facility specializing in neurological disorders and cardiovascular disease prevention. The center demonstrates particular expertise in multiple sclerosis research, investigating novel therapeutic approaches including BTK inhibitors and combination therapies for both relapsing and progressive forms of the disease. The facility also maintains a strong focus on acute cerebrovascular events and stroke prevention strategies.
- Multiple sclerosis therapeutics - investigating long-term safety and efficacy of disease-modifying treatments for relapsing and progressive MS
- Stroke prevention and acute ischemic stroke management - evaluating novel anticoagulants and Factor XIa inhibitors
- Migraine prevention research - clinical trials for both chronic and episodic migraine using botulinum toxin therapies
- Cardiovascular disease prevention - primary prevention strategies for atherosclerotic cardiovascular disease
The center's comprehensive approach extends to autoimmune conditions, including cutting-edge research in Type 1 diabetes mellitus, where investigators are evaluating therapies aimed at preserving endogenous insulin secretion in newly diagnosed patients. With its multidisciplinary expertise spanning neurology, cerebrovascular medicine, and metabolic disorders, Nemocnice Jihlava serves as a key site for Phase 3 clinical trials focused on improving outcomes in nervous system diseases and cardiovascular risk reduction.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 82 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 78 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Novartis Pharma AG2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG7trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nemocnice Jihlava prispevkova organizace
lock Showing 1 of 38 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis | Biogen Idec Research Limited | Phase II | Not Recruiting | Oct 2023 | Feb 2026 |
IMP list
lock Showing 1 of 82 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ocrelizumab | 6 | Unknown | 2018-05-02 | 2025-10-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.